Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37959298

about

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes.B-cell receptor signaling as a driver of lymphoma development and evolution.The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia.The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.VDJSeq-Solver: in silico V(D)J recombination detection tool.Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies p110δ PI3 kinase pathway: emerging roles in cancer.Associations between dietary patterns and gene expression profiles of healthy men and women: a cross-sectional study.Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies.Overview of recent developments in chronic lymphocytic leukemia.Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia.GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia.Clonal expansion in B-CLL: fungal drivers or self-service?BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia.Modeling the chronic lymphocytic leukemia microenvironment in vitro.Functional proteomic insights in B-cell chronic lymphocytic leukemia.The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.Expression of Bruton's tyrosine kinase in B-cell neoplasms evaluated by flow cytometry.

P2860

Q33978930-64071B69-9996-4637-A10D-CE0972B77A8C Q34342465-738C1611-3574-409B-A5E7-7045B5F947C6 Q34398579-25DC5F93-23E7-459B-A901-BF0672C245B2 Q35489417-A1A70014-1BBD-43BB-A3EF-D04529C37E7B Q35583403-FB88EFE4-79A7-4DA2-9EEB-B982F3B9336E Q35583972-03A73531-3935-48D3-9F26-C41EEF74FA19 Q35958056-181EF16C-BE77-4AD6-8DC1-F3DB21981D50 Q36602853-8F60606B-F39E-47A8-B697-9F0FC88051D8 Q36647928-8A65033B-B125-4023-9E13-0799EA28577E Q36686403-E779D799-E543-48EE-8EEF-FF683E509F4D Q36936456-92F3F477-E16E-4880-9B4F-8297CE287FC2 Q37422201-902F602C-CA27-459F-9089-CF4A610FC70D Q38025162-A7DBB121-6172-42FA-957B-886786977250 Q38056832-B87653D9-6098-424F-A665-BE19E6FB7929 Q38074145-5456AD69-8FE5-4B59-92A2-310F2F57A380 Q38101590-4B34454A-B23A-47B2-8B9D-45D2D12B6020 Q38872127-E42F087D-29D8-47D6-917B-32D8886FC4F7 Q38984569-BFBEDAFF-859D-466B-A614-4596CA6363E9 Q39048554-66601A75-46DD-48DF-A693-75F3A466FA67 Q39180275-F2D5DED9-2E8A-4BA5-95D0-D3DF8664AD1E Q42320922-651F5269-459A-4AE1-B257-5D84B54CAE7C Q47424531-46E275F6-8BE1-4BE6-A54D-46BB5443BF13 Q51232163-8A8ED6C8-922E-4CE8-A905-B4A0D7B83479

P2860

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37959298

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

@en

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

@nl

type

label

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

@en

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

@nl

prefLabel

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

@en

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

@nl

P1433

Q37959298-49CAF5ED-6EB4-4B5A-A778-A02F95B6F601

P1476

Q37959298-05A7879A-86BE-4874-B562-F31177AFE9CE

P2093

Q37959298-7A62DF1D-E65A-429E-B8AD-ADC677EF7F4C

P2860

Q37959298-0802ABB5-B47B-49DE-9DB4-85FAAB655F73

Q37959298-0DB64845-BF25-4765-8EA5-2ADE8E8BCBD8

Q37959298-0DBE3334-1129-4D31-B460-E954A1EE5BD5

Q37959298-0EA517C3-64E7-4A86-BCC3-5C92D1B9BEED

Q37959298-1562C128-3156-4088-8F88-99C99D7392CD

Q37959298-184E9FA0-DF2C-4989-B89E-0922CFA3F182

Q37959298-1915F434-1A85-4D23-B21B-61C4F9C962A5

Q37959298-1C74AB5A-073B-43B0-92C7-21FA274085E8

Q37959298-21A8C1D4-9FEF-4F54-B2A2-696F92D8F9C3

Q37959298-2205BC08-F1A6-4DA4-9F02-62AFB7824875

P2888

Q37959298-68C81AA2-F1C7-42C2-9964-1307E2B3E7B5

P304

Q37959298-3624048C-CEB4-4F3C-8286-362344C1FF49

P31

Q37959298-AA3DD51A-BC44-4D86-861E-3E11EACFFA77

P356

Q37959298-1A480646-CD23-4FD4-A85A-D63E8692DB64

P433

Q37959298-37E1D3B4-E97D-4682-AA43-87DF65B31794

P478

Q37959298-846A43A5-E2B2-4FA8-9B72-4A13C12AAE31

P577

Q37959298-DA29CA4D-78B5-42B8-BBF5-8BF9732991E6

P698

Q37959298-886CE6B9-8811-4735-B1B7-4839C133847C

P921

Q37959298-3157C9E1-7361-4566-A8E9-0A5CB09C3C90

Q37959298-711D502A-B4D6-48F1-9AA8-AE5A85D23050

P356

S11899-011-0104-Z

P1433

Current hematologic malignancy reports

P1476

Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

@en

P2093

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

P2860

ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain

Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk

Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk

PI3K in lymphocyte development, differentiation and activation

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation

P2888

s11899-011-0104-z

P304

26-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-011-0104-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22105489

http://www.w3.org/2001/XMLSchema#string

P921